Sustainability & Climate

Austrian firm AOP Health secures nationwide access for its rapid heart rate drug, Rapiblyk™, by partnering with top US distributors. What does this mean for critical care?

As billions are invested in broadband, the Fiber Broadband Association releases a new guide to help builders avoid costly mistakes and accelerate deployment.

With a new name and a laser focus on its lead hemophilia A drug, Metagenomi Therapeutics signals a major shift from platform tech to clinical powerhouse.

Carlsmed's AI-driven aprevo® platform shows massive surgeon adoption and market growth, signaling a new era of personalized, cost-effective spine care.

A partnership between Pacific General and S Food will inject global innovation and Korean-inspired products into an 84-year-old American deli brand.

The EdTech giant is unveiling an integrated ecosystem with new AI capabilities and a Microsoft Teams solution at five major international trade shows.

ConcertAI and Foundation Medicine unite to create a huge dataset of 500k patients, using AI to accelerate the hunt for new life-saving cancer drugs.

Private equity firm Sole Source Capital acquires cybersecurity provider Brite, signaling a major 'buy-and-build' play in a booming, fragmented market.

FDA clears a novel two-part immunotherapy that paints solid tumors with a synthetic target, unleashing a powerful CAR T-cell attack in a new clinical trial.

Promising new 96-week data shows Vir's therapy could redefine care for severe hepatitis delta, as its oncology pipeline and financial runway also advance.

Erasca reports promising early data for its pan-RAS inhibitor, ERAS-0015, showing tumor shrinkage at low doses and shaking up the competitive landscape.

With preliminary Q1 revenue of $103.7M, Twist Bioscience beats forecasts, setting a bullish tone ahead of its full earnings report on February 2nd.

The genomics leader posted a 41% revenue surge in 2025 and projects profitability, yet its stock tumbled on what some see as conservative 2026 guidance.

With a major strategic pivot complete, Gibraltar Industries' leadership will outline its 2026 playbook to investors at a key 'New Ideas' conference.

With its new thalassemia drug AQVESME launching, Agios aims for blockbuster status while navigating a key safety warning and advancing a broad pipeline.

As a foundational CFO steps down, XOMA Royalty brings in biotech veteran Jeffrey Trigilio to enhance its dealmaking strategy and expand its royalty portfolio.

With pivotal cancer drug data looming and a new nuclear supply chain, Bicycle Therapeutics is betting big on its novel platform. Will 2026 be its breakout year?

IVECO and PlusAI are deploying Level 4 autonomous trucks on a key Spanish freight corridor, heralding a new era for logistics in Southern Europe.

Cytek Biosciences reports preliminary 2025 revenue of $201M, beating estimates with a major Q4 growth surge ahead of its key J.P. Morgan presentation.

CoinEx's consistent token burning removes over 166M CET in a year, signaling a long-term commitment to scarcity and value in a competitive market.